Proven efficacy in the major effectiveness parameters of relapsing MS … confirmed in pioneering clinical trials. 37% reduction of disability progression, 32% reduction of relapse rate, 74% reduction of Number of T1 Gd lesions, 55% reduction of progression of brain atrophy, 47% reduction of deterioration of cognitive functions. Avonex.
Abstract
Interferon beta-1a, Biogen, Image of a photo reel with the same middle aged white woman with a positive expression on her face, doing various activities. For example, she is reading, working, talking on the phone, and pondering.
